Skip to main content
. 2018 Mar 20;170(2):257–270. doi: 10.1007/s10549-018-4757-3

Fig. 3.

Fig. 3

Receiver-operating characteristic (ROC) curves for the plasma and serum 4-miRNA panels for discriminating BC patients from HCs. AUC: area under the curve. a Combined two cohorts from the training and testing phases (A1: plasma from 170 BC patients and 170 HCs; A2: Serum from 174 BC patients and 172 HCs); b Training phase (B1: plasma from 24 BC patients and 24 HCs; B2: Serum from 24 BC patients and 24 HCs); c Testing phase (C1: plasma from 146 BC patients and 146 HCs; C2: Serum from 150 BC patients and 148 HCs); d External validation phase (D1: plasma from 30 BC patients and 30 HCs; D2: Serum from 30 BC patients and 30 HCs)